NCT03431584

Brief Summary

The rhizarthrosis, or the degenerative osteoarthritis of the trapezo-metacarpal joint, is a frequent degenerative osteoarthritis. The treatment associates not pharmacological measures, such as resting relative of the joint, the orthosis of rest, glazing and pharmacological measures such analgesic, anti-inflammatory not steroidal per bones or premises, even infiltrations cortisone or by hyaluronic acid. No study has, for the moment, tested the interest of the combination of cortisone and hyaluronic acid in rhizarthrosis. In view of the current publications, we propose to carry out a study on two arms, with corticosteroids in reference arm; the experimental arm is the combination of hyaluronic acid and cortisone.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started May 2018

Longer than P75 for phase_4

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 6, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 13, 2018

Completed
3 months until next milestone

Study Start

First participant enrolled

May 11, 2018

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 28, 2021

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 16, 2021

Completed
3.8 years until next milestone

Results Posted

Study results publicly available

September 29, 2025

Completed
Last Updated

December 2, 2025

Status Verified

November 1, 2025

Enrollment Period

3 years

First QC Date

February 6, 2018

Results QC Date

October 30, 2023

Last Update Submit

November 14, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Analogical Visual Scale of Pain (VAS)

    Analogical visual scale of pain (VAS) To 0 cm (no pain) form 10 cm (worst pain imaginable)

    3 month post infiltration

Study Arms (2)

Infiltration of corticosteroids

ACTIVE COMPARATOR
Drug: infiltration of corticosteroids

Infiltration of corticosteroids and hyaluronic acid

EXPERIMENTAL
Drug: infiltration of corticosteroids and hyaluronic acid

Interventions

infiltration of corticosteroids

Infiltration of corticosteroids

infiltration of corticosteroids and hyaluronic acid

Infiltration of corticosteroids and hyaluronic acid

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults, ≥ 40 years
  • Pain located at the root of the thumb (near the wrist) and awakened by direct pressure and movement
  • Pain resistant to well-conducted medical treatment, with analgesics, NSAIDs, icing with pain (analog visual scale) ≥ 4 for more than 3 months
  • Radiological findings (kapandji face + profile incidence) typical of rhizarthrosis, stage II or III of Eaton and Litter, with at least 2 of the following 5 radiological elements observed on the trapeziometacarpal joint:
  • marginal osteophyte
  • pinching of the joint space
  • sclerosis of the subchondral space
  • subchondral kyst
  • absence of osteopenia
  • Patient with the ability to understand the protocol and signed informed consent
  • Patient receiving social security

You may not qualify if:

  • Known allergy to any of the products (corticosteroids or hyaluronic acid) including its excipients (methyl parahydroxybenzoate, propyl parahydroxybenzoate, benzyl alcohol)
  • Patients with symptomatic bilateral rhizarthrosis
  • Scaphoid-trapezial arthrosis
  • Local or general infection
  • Severe coagulation disorders, ongoing anticoagulant therapy
  • severe and / or uncontrolled hypertension
  • Earlier local surgery
  • Associated inflammatory rheumatism
  • Tendinopathy of De Quervain, thumb to jump associated
  • Infiltrations earlier than 6 months
  • Diabetes imbalanced
  • Live vaccines
  • Severe water and / or sodium retention (hypernatremia), particularly in cases of heart failure, decompensated liver failure (edema and ascites failure)
  • Pregnant or lactating women
  • Immunocompromised or hemodialysis patients
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

CH Cholet

Cholet, 49300, France

Location

CHD Vendée

La Roche-sur-Yon, 85925, France

Location

CH Le Mans

Le Mans, 72037, France

Location

CHU Nantes

Nantes, 44000, France

Location

Related Publications (2)

  • Cormier G, Le Goff B, Denis A, Varin S, Auzanneau L, Dimet J, Le Thuaut A. Corticosteroids injections versus corticosteroids with hyaluronic acid injections in rhizarthrosis: the randomised multicentre RHIZ'ART trial study protocol. BMJ Open. 2019 Jan 9;9(1):e022553. doi: 10.1136/bmjopen-2018-022553.

    PMID: 30782680BACKGROUND
  • Cormier G, Denis A, Leske C, Varin S, Dimet J, Planche L, Le Goff B. Improvement of rhizarthrosis pain management with the infiltration of hyaluronic acid and corticosteroids versus corticosteroids alone. Joint Bone Spine. 2025 Jul;92(4):105849. doi: 10.1016/j.jbspin.2025.105849. Epub 2025 Jan 30.

MeSH Terms

Interventions

Hyaluronic Acid

Intervention Hierarchy (Ancestors)

GlycosaminoglycansPolysaccharidesCarbohydrates

Results Point of Contact

Title
Dr. Grégoire CORMIER
Organization
Centre Hospitalier Departemental Vendée

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 6, 2018

First Posted

February 13, 2018

Study Start

May 11, 2018

Primary Completion

May 28, 2021

Study Completion

December 16, 2021

Last Updated

December 2, 2025

Results First Posted

September 29, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations